Anderson, C. M., Lee, C. M., Saunders, D., Curtis, A. E., Dunlap, N. E., Nangia, C., Lee, A.S., Kovoor, P., Bar-Ad, V., Pedadda, A.V., Holmlund, J., Downs, M., & Sonis, S. T. (2022). Two-year tumor outcomes of a phase 2B, randomized, double-blind trial of avasopasem manganese (GC4419) versus placebo to reduce severe oral mucositis owing to concurrent radiation therapy and cisplatin for head and neck cancer. International Journal of Radiation Oncology Biology Physics, 114(3),416-421. https://doi.org/10.1016/j.ijrobp.2022.06.063
Jung, Y. S., Park, E. Y., & Sohn, H. O. (2019). Oral health status and oral health-related quality of life according to presence or absence of mucositis in head and neck cancer patients. Journal of Cancer Prevention, 24(1), 43-47. https://doi.org/10.15430/JCP.2019.24.1.43.
Yin, J., Xie, J., Lin, J., Weng, C., Lu, S., Xu, P., Zhanga, S., Luoa, C., Huanga, Y., Lia, L., Langa, J., & Feng, M. (2022). Evaluation of the efficacy of the anti-ulcer oral mucosal protective agent RADoralex® in the prevention and treatment of radiation-induced oral mucosal reactions induced during treatment of nasopharyngeal carcinoma. Cancer Biology & Therapy, 23(1), 27-33. https://doi.org/10.1080/15384047.2021.2013704